Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
01:05pm, Friday, 20'th Dec 2024
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 300 points on Friday.
Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss
12:52pm, Friday, 20'th Dec 2024
Novo Nordisk A/S NVO is seeing its stock spiral downwards, with shares plummeting 20% early Friday following the release of Phase 3 trial data.
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
12:27pm, Friday, 20'th Dec 2024
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the highes
Novo Nordisk stock just tanked 25%: here's what happened
12:26pm, Friday, 20'th Dec 2024
Novo Nordisk A/S (CPH: NOVO-B) is being punished this morning after posting a disappointing update related to CagriSema. The pharmaceutical behemoth said its experimental weight-loss treatment helped
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
12:20pm, Friday, 20'th Dec 2024
Bad news for Novo Nordisk (NVO -17.77%) Friday was good news for Eli Lilly (LLY 4.88%) and Viking Therapeutics (VKTX 5.86%), its two main rivals in the field of weight loss drugs. This morning, Novo r
Novo Nordisk shares plummet after weight-loss drug's disappointing trial results
12:00pm, Friday, 20'th Dec 2024
Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.
Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says
11:27am, Friday, 20'th Dec 2024
Emily Field, Barclays' head of European pharmaceutical research, reacts to the selloff in Novo Nordisk's shares after its experimental obesity shot CagriSema failed to meet expectations. She speaks on
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
10:31am, Friday, 20'th Dec 2024
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Novo Nordisk stock plunges on obesity shot trial results
10:30am, Friday, 20'th Dec 2024
Novo Nordisk (NVO) is falling by over 20% in Friday's pre-market trading after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted in i
Novo Nordisk Stock Eyes Worst Day, Week on Record
10:29am, Friday, 20'th Dec 2024
Novo Nordisk A/S (NYSE:NVO) stock is down 18.9% to trade at $82.25 at last check, after the pharmaceutical company's weight loss drug CagriSema missed expectations of a late-stage study.
Novo Nordisk: CagriSema Underwhelms In REDEFINE-1 Trial
10:08am, Friday, 20'th Dec 2024
Shares of Novo Nordisk A/S are down after underwhelming REDEFINE-1 trial results. The results were positive, but underperformed company and market expectations (including my own). The trial's flexible
PCE Data Lower Than Expected, NVO Falls on New Obesity Drug, AFRM Upgraded
09:40am, Friday, 20'th Dec 2024
Jenny Horne joins the Futures show with live reaction to the latest PCE inflation data. November rate rose just 0.1% from October, but on an annual basis checked in at 2.4% On the stock front, Novo No
Novo Nordisk Stock: A Rare Buying Opportunity
09:15am, Friday, 20'th Dec 2024
As I'm writing these lines, Novo Nordisk A/S stock is down about 16% on the pre-market session after the news came out that CagriSema delivered disappointing trial results. I think this selloff is a r
Novo Nordisk shares drop after weight loss drug trial disappoints
09:13am, Friday, 20'th Dec 2024
Novo Nordisk (NYSE:NVO) shares plunged more than 20% before Friday's opening bell after the drugmaker reported results from a late-stage trial of its weight loss drug CagriSema that fell short of ex
Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight Loss Drug
08:30am, Friday, 20'th Dec 2024
Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current lineup of Ozemp
